LEO 32731

Drug Profile

LEO 32731

Alternative Names: LEO32731; LP-0058

Latest Information Update: 26 Aug 2016

Price : $50

At a glance

  • Originator LEO Pharma
  • Class Antipsoriatics
  • Mechanism of Action Interferon gamma inhibitors; Interleukin 10 stimulants; Interleukin 5 inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Psoriasis
  • Phase I Atopic dermatitis

Most Recent Events

  • 16 Aug 2016 Leo Pharma terminates a phase I trial (In volunteers) in United Kingdom due to tolerability issues (NCT02753218)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Psoriasis(In volunteers) in United Kingdom (PO, Capsule)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Psoriasis(In volunteers) in United Kingdom (PO, Liquid)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top